Decoy Therapeutics, Inc. (DCOY)
1.23
+0.13
(+11.82%)
USD |
NASDAQ |
Oct 29, 16:00
1.22
-0.01
(-0.81%)
Pre-Market: 09:23
Decoy Therapeutics Shareholders Equity (Quarterly) : 4.321M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 4.321M |
| March 31, 2026 | 3.877M |
| December 31, 2025 | 5.889M |
| September 30, 2025 | 4.248M |
| June 30, 2025 | -0.8297M |
| March 31, 2025 | 0.0619M |
| December 31, 2024 | 1.512M |
| September 30, 2024 | 2.925M |
| June 30, 2024 | 2.375M |
| March 31, 2024 | 3.650M |
| December 31, 2023 | 5.287M |
| September 30, 2023 | 6.084M |
| June 30, 2023 | 8.414M |
| March 31, 2023 | 5.559M |
| December 31, 2022 | 10.38M |
| September 30, 2022 | 16.61M |
| June 30, 2022 | 30.88M |
| March 31, 2022 | |
| December 31, 2021 | 38.72M |
| September 30, 2021 | 42.65M |
| June 30, 2021 | 45.85M |
| March 31, 2021 | 48.78M |
| December 31, 2020 | 22.16M |
| September 30, 2020 | 20.61M |
| Date | Value |
|---|---|
| June 30, 2020 | 16.86M |
| March 31, 2020 | 18.00M |
| December 31, 2019 | 10.58M |
| September 30, 2019 | 9.737M |
| June 30, 2019 | 6.101M |
| March 31, 2019 | 7.273M |
| December 31, 2018 | -1.271M |
| September 30, 2018 | 11.05M |
| June 30, 2018 | 13.41M |
| March 31, 2018 | 21.89M |
| December 31, 2017 | 29.11M |
| September 30, 2017 | 36.18M |
| June 30, 2017 | 44.50M |
| March 31, 2017 | 52.23M |
| December 31, 2016 | 59.32M |
| September 30, 2016 | 66.03M |
| June 30, 2016 | 74.82M |
| March 31, 2016 | 84.17M |
| December 31, 2015 | 92.19M |
| September 30, 2015 | 98.00M |
| June 30, 2015 | 104.65M |
| March 31, 2015 | 110.08M |
| December 31, 2014 | 34.49M |
| September 30, 2014 | 35.95M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 3.604B |
| Anika Therapeutics, Inc. | 137.28M |
| Savara, Inc. | 143.66M |
| Vericel Corp. | 370.04M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 9.001M |
| Total Liabilities (Quarterly) | 4.680M |
| Current Ratio | 1.832 |
| Net Debt Paydown Yield | 0.59% |